The impact of implementing current treatment modalities and female sex on gastric cancer outcomes, 2000–2016: a longitudinal nationwide cohort study

References

• Ang TL, Fock KM. Clinical epidemiology of gastric cancer. Singapore Med J. 2014;55(12):621–628. doi: 10.11622/smedj.2014174.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi: 10.1016/S0140-6736(17)33326-3.
   PubMed Web of Science ®Google Scholar
• Griniatsos J, Trafalis D. Differences in gastric cancer surgery outcome between east and west: differences in surgery or different diseases? J Buon. 2018;23(5):1210–1215.
   PubMed Web of Science ®Google Scholar
• Finnish Cancer Registry - Cancers statistics. [cited 2023 Feb 28]. Available from: https://cancerregistry.fi/statistics/cancer-statistics/.
   Google Scholar
• Wong MCS, Huang J, Chan PSF, et al. Global incidence and mortality of gastric cancer, 1980-2018. JAMA Netw Open. 2021;4(7):e2118457. doi: 10.1001/jamanetworkopen.2021.18457.
   PubMed Web of Science ®Google Scholar
• Holster IL, Aarts MJ, Tjwa ETTL, et al. Trend breaks in incidence of non-cardia gastric cancer in The Netherlands. Cancer Epidemiol. 2014;38(1):9–15. doi: 10.1016/j.canep.2013.11.001.
   PubMed Web of Science ®Google Scholar
• Camargo MC, Anderson WF, King JB, et al. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut. 2011;60(12):1644–1649. doi: 10.1136/gut.2010.236737.
   PubMed Web of Science ®Google Scholar
• Suh YS, Lee J, Woo H, et al. National cancer screening program for gastric cancer in Korea: nationwide treatment benefit and cost. Cancer. 2020;126(9):1929–1939. doi: 10.1002/cncr.32753.
   PubMed Web of Science ®Google Scholar
• Hamashima C, Kato K, Miyashiro I, et al. Update version of the japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2018;48(7):673–683. doi: 10.1093/jjco/hyy077.
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyashiro I, Ishikawa T, et al. Determinant factors on differences in survival for gastric cancer between the US and Japan using nationwide databases. J Epidemiol. 2021;31(4):241–248. doi: 10.2188/jea.JE20190351.
   Google Scholar
• Arnold M, Morgan E, Bardot A, et al. International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study). Gut. 2022;71(8):1532–1543. doi: 10.1136/gutjnl-2021-325266.
   PubMed Web of Science ®Google Scholar
• Kumar S, Metz DC, Ellenberg S, et al. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology. 2020;158(3):527–536.e7. doi: 10.1053/j.gastro.2019.10.019.
   PubMed Web of Science ®Google Scholar
• Kim HW, Kim JH, Lim BJ, et al. Sex disparity in gastric cancer: female sex is a poor prognostic factor for advanced gastric cancer. Ann Surg Oncol. 2016;23(13):4344–4351. doi: 10.1245/s10434-016-5448-0.
   PubMed Web of Science ®Google Scholar
• Choi Y, Kim N, Kim KW, et al. Sex-based differences in histology, staging, and prognosis among 2983 gastric cancer surgery patients. World J Gastroenterol. 2022;28(9):933–947. doi: 10.3748/wjg.v28.i9.933.
   PubMed Web of Science ®Google Scholar
• Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35(7):1059–1064. doi: 10.1016/s0959-8049(99)00076-3.
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–730. doi: 10.1056/NEJMoa010187.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med. 2006;355(1):11–20. doi: 10.1056/NEJMoa055531.
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–1820. doi: 10.1056/NEJMoa072252.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra. Lancet. 2019;393(10184):1948–1957. doi: 10.1016/S0140-6736(18)32557-1.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–v49. doi: 10.1093/annonc/mdw350.
   PubMedGoogle Scholar
• Songun I, Putter H, Kranenbarg EMK, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–449. doi: 10.1016/S1470-2045(10)70070-X.
   PubMed Web of Science ®Google Scholar
• van Putten M, Nelen SD, Lemmens VEPP, et al. Overall survival before and after centralization of gastric cancer surgery in The Netherlands. Br J Surg. 2018;105(13):1807–1815. doi: 10.1002/bjs.10931.
   PubMed Web of Science ®Google Scholar
• Pasquer A, Renaud F, Hec F, et al. Is centralization needed for esophageal and gastric cancer patients with low operative risk? A nationwide study. Ann Surg. 2016;264(5):823–830. doi: 10.1097/SLA.0000000000001768.
   PubMed Web of Science ®Google Scholar
• Nieminen A, Kokkola A, Ylä-Liedenpohja J, et al. Early gastric cancer: clinical characteristics and results of surgery. Dig Surg. 2009;26(5):378–383. doi: 10.1159/000226765.
   PubMed Web of Science ®Google Scholar
• Junttila A, Helminen O, Kairaluoma V, et al. Implementation of multimodality therapy and minimally invasive surgery: short- and long-term outcomes of gastric cancer surgery in Medium-Volume center. J Gastrointest Surg. 2022;26(10):2061–2069. doi: 10.1007/s11605-022-05437-3.
   PubMed Web of Science ®Google Scholar
• Sund R. Quality of the finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40(6):505–515. doi: 10.1177/1403494812456637.
   PubMed Web of Science ®Google Scholar
• Leinonen MK, Miettinen J, Heikkinen S, et al. Quality measures of the population-based finnish cancer registry indicate sound data quality for solid malignant tumours. Eur J Cancer. 2017;77:31–39. doi: 10.1016/j.ejca.2017.02.017.
   PubMed Web of Science ®Google Scholar
• Nomesco Classification of Surgical Procedures. 2011 [cited 2023 Sep 28]. Available from: https://nhwstat.org/publications/ncsp-classification-surgical-procedures.
   Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi: 10.3322/caac.21388.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KLA new method of classifying prognostic comorbidity in longitudinal studies: development and validation, et al. 1987. p. 373-383. doi: 10.1016/0021-9681(87)90171-8.
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi: 10.1097/01.mlr.0000182534.19832.83.
   PubMed Web of Science ®Google Scholar
• Pylväläinen J, Talala K, Murtola T, et al. Charlson comorbidity index based on hospital episode statistics performs adequately in predicting mortality, but its discriminative ability diminishes over time. Clin Epidemiol. 2019;11:923–932. doi: 10.2147/CLEP.S218697.
   PubMed Web of Science ®Google Scholar
• Holmebakk T, Frykholm G, Viste A. Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: a retrospective audit. Eur J Surg Oncol. 2010;36(7):610–616. doi: 10.1016/j.ejso.2010.05.006.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO. Lancet Oncol. 2016;17(12):1697–1708. doi: 10.1016/S1470-2045(16)30531-9.
   PubMed Web of Science ®Google Scholar
• Moore JL, Kumar S, Santaolalla A, et al. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens. Eur J Cancer. 2022;163:180–188. doi: 10.1016/j.ejca.2021.12.021.
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Hermans J, Sasako M, et al. Extended Lymph-Node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–914. doi: 10.1056/NEJM199903253401202.
   PubMed Web of Science ®Google Scholar
• Kauppila JH, Ohtonen P, Karttunen TJ, et al. Finnish national Esophago-Gastric cancer cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland. BMJ Open. 2019;9(1):e024094. doi: 10.1136/bmjopen-2018-024094.
   PubMed Web of Science ®Google Scholar
• Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the japanese gastric cancer association (2001–2007). Gastric Cancer. 2018;21(1):144–154. doi: 10.1007/s10120-017-0716-7.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Ishiguro R, Miyauchi W, et al. Appraisal of long-time outcomes after curative surgery in elderly patients with gastric cancer: a propensity score matching analysis. BMC Surg. 2021;21(1):33. doi: 10.1186/s12893-021-01046-0.
   PubMed Web of Science ®Google Scholar
• Claassen YHM, Dikken JL, Hartgrink HH, et al. North european comparison of treatment strategy and survival in older patients with resectable gastric cancer: a EURECCA upper gastrointestinal group analysis. Eur J Surg Oncol. 2018;44(12):1982–1989. doi: 10.1016/j.ejso.2018.09.014.
   PubMed Web of Science ®Google Scholar
• Snyder RA, Penson DF, Ni S, et al. Trends in the use of evidence-based therapy for resectable gastric cancer. J Surg Oncol. 2014;110(3):285–290. doi: 10.1002/jso.23635.
   PubMed Web of Science ®Google Scholar
• Koo DH, Ryu MH, Ryoo BY, et al. Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution. Gastric Cancer. 2015;18(2):346–353. doi: 10.1007/s10120-014-0385-8.
   PubMed Web of Science ®Google Scholar
• Camargo MC, Goto Y, Zabaleta J, et al. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(1):20–38. doi: 10.1158/1055-9965.EPI-11-0834.
   PubMed Web of Science ®Google Scholar
• Kalff MC, Wagner AD, Verhoeven RHA, et al. Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the dutch upper GI cancer audit. Gastric Cancer. 2022;25(1):22–32. doi: 10.1007/s10120-021-01225-1.
   PubMed Web of Science ®Google Scholar
• Assumpcao PP, Barra WF, Ishak G, et al. The diffuse-type gastric cancer epidemiology enigma. BMC Gastroenterol. 2020;20(1):223. doi: 10.1186/s12876-020-01354-4.
   PubMed Web of Science ®Google Scholar
• van der Kaaij RT, Koemans WJ, van Putten M, et al. A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in The Netherlands between 1989 and 2015. Eur J Cancer. 2020;130:23–31. doi: 10.1016/j.ejca.2020.02.017.
   PubMed Web of Science ®Google Scholar
• Kauppila JH. Completeness of esophageal cancer diagnosis in the finnish cancer registry and hospital discharge registry, a nationwide study in Finland. Acta Oncol. 2020;59(11):1329–1332. doi: 10.1080/0284186X.2020.1792547.
   PubMed Web of Science ®Google Scholar
• Maharjan U, Kauppila JH. Gastric cancer completeness in finnish cancer registry and finnish patient registry: a population-based nationwide retrospective cohort study. BMJ Open. 2022;12(4):e056320-e056320. doi: 10.1136/bmjopen-2021-056320.
   Web of Science ®Google Scholar
• Lunkka P, Malila N, Ryynänen H, et al. Accuracy of finnish cancer registry colorectal cancer data: a comparison between registry data and clinical records. Scand J Gastroenterol. 2021;56(3):247–251. doi: 10.1080/00365521.2020.1867893.
   PubMed Web of Science ®Google Scholar